Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Non-Current Deffered Revenue (2017 - 2025)

vTv Therapeutics' Non-Current Deffered Revenue history spans 9 years, with the latest figure at $18.7 million for Q4 2025.

  • For Q4 2025, Non-Current Deffered Revenue changed 0.0% year-over-year to $18.7 million; the TTM value through Dec 2025 reached $18.7 million, changed 0.0%, while the annual FY2025 figure was $18.7 million, 0.0% changed from the prior year.
  • Non-Current Deffered Revenue for Q4 2025 was $18.7 million at vTv Therapeutics, roughly flat from $18.7 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $18.7 million in Q2 2022 and bottomed at $9000.0 in Q2 2021.
  • The 5-year median for Non-Current Deffered Revenue is $18.7 million (2022), against an average of $15.6 million.
  • The largest annual shift saw Non-Current Deffered Revenue tumbled 99.12% in 2021 before it skyrocketed 207333.33% in 2022.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $9000.0 in 2021, then surged by 207333.33% to $18.7 million in 2022, then changed by 0.0% to $18.7 million in 2023, then changed by 0.0% to $18.7 million in 2024, then changed by 0.0% to $18.7 million in 2025.
  • Per Business Quant, the three most recent readings for VTVT's Non-Current Deffered Revenue are $18.7 million (Q4 2025), $18.7 million (Q3 2025), and $18.7 million (Q2 2025).